Weekly Investment Analysts’ Ratings Changes for Terns Pharmaceuticals (TERN)

Posted by Scott Moore on Mar 31st, 2026

Terns Pharmaceuticals (NASDAQ: TERN) recently received a number of ratings updates from brokerages and research firms:

3/31/2026 – Terns Pharmaceuticals had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $53.00 price target on the stock, down from $56.00.
3/30/2026 – Terns Pharmaceuticals had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $53.00 price target on the stock, down from $56.00.
3/27/2026 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by Weiss Ratings.
3/27/2026 – Terns Pharmaceuticals was downgraded by Barclays PLC from “strong-buy” to “hold”.
3/27/2026 – Terns Pharmaceuticals was downgraded by Mizuho from “strong-buy” to “hold”.
3/26/2026 – Terns Pharmaceuticals was downgraded by TD Cowen from “buy” to “hold”. They now have a $53.00 price target on the stock.
3/26/2026 – Terns Pharmaceuticals was downgraded by Citizens Jmp from “market outperform” to “hold”.
3/25/2026 – Terns Pharmaceuticals had its “neutral” rating reaffirmed by HC Wainwright. They now have a $53.00 price target on the stock, down from $60.00.
3/21/2026 – Terns Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
2/20/2026 – Terns Pharmaceuticals was upgraded by TD Cowen to “strong-buy”.
2/14/2026 – Terns Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
2/9/2026 – Terns Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $58.00 price target on the stock.

Insider Buying and Selling

In other news, CEO Amy L. Burroughs sold 14,583 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the completion of the sale, the chief executive officer owned 288,976 shares of the company’s stock, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the sale, the insider owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 170,409 shares of company stock worth $6,563,769. Company insiders own 1.50% of the company’s stock.

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.